EAS: Liquid Chromatographic Gradient Method Allowances Provided by General Chapter, USP <621> Chromatography

Importance of Topic

Liquid chromatographic gradient method allowances introduced in USP General Chapter <621> provide regulatory flexibility and support method modernization for pharmaceutical analysis. By permitting adjustments to key parameters, these guidelines help laboratories maintain monograph compliance while leveraging modern LC platforms to improve throughput, reduce solvent consumption and maintain robust impurity separations.

Objectives and Study Overview

This study demonstrates the application of USP <621> gradient allowances to an antiviral drug impurities monograph for abacavir sulfate. The goal was to translate a legacy HPLC gradient method into an optimized UHPLC protocol, verify system suitability across instruments and evaluate gains in run time, solvent usage and sample throughput.

Methodology and Instrumentation

The System Suitability Test (SST) mixture was prepared following the official abacavir sulfate monograph. Relative retention times were measured on two LC platforms:

• Waters Alliance HPLC (3.9 × 150 mm, 5 µm; dwell volume 1.145 mL)
• Waters ACQUITY UHPLC (2.1 × 75 mm, 2.5 µm; dwell volume 0.073 mL)

Gradient adjustment formulas were applied to calculate new flow rate, injection volume, gradient time and dwell volume offsets. The OBD™ Column Calculator facilitated column dimension translation between platforms.

Main Results and Discussion

Retention times and critical peak resolutions on the UHPLC system matched the monograph criteria when using adjusted parameters. Key findings included:

• Equivalent relative retention times across both instruments
• Resolution of the critical impurity pair meeting USP thresholds

Table 2 data indicated a reduction in run time by over 50%, halving of solvent and sample consumption, and an increase in sample runs per hour compared to the original HPLC method.

Benefits and Practical Applications

Implementing USP <621> gradient allowances yields multiple advantages:

• Method flexibility across diverse LC platforms
• Enhanced laboratory efficiency through shorter cycle times
• Lower operating costs due to reduced solvent use
• Maintained regulatory compliance and method robustness

Future Trends and Potential Applications

Anticipated developments include broader adoption of adaptive gradient methods, integration of automated column and method calculators, and application of AI-driven optimization for greener, high-throughput pharmaceutical analyses. Continued updates to pharmacopeial standards will further enable seamless transitions to emerging chromatographic technologies.

Conclusion

USP General Chapter <621> gradient method allowances facilitate successful modernization of legacy monograph methods. By applying validated adjustment formulas, laboratories can leverage UHPLC advantages—faster analyses, lower solvent consumption and increased throughput—while ensuring monograph compliance and robust impurity separations.

References

• Layton C.E., Rainville P.D. Achieving Method Modernization with the New Liquid Chromatographic Gradient Allowances Provided by USP General Chapter <621> Chromatography and the Alliance HPLC System. Waters Technologies Corporation, 2023.
• United States Pharmacopeia. General Chapter <621> Chromatography. Official date: December 1, 2022.
• United States Pharmacopeia. Abacavir Sulfate Monograph. Official date: May 1, 2020.
• Waters Technologies Corporation. Preparative OBD™ Column Calculator. Accessed January 15, 2022.